(Sharecast News) - Genedrive said on Friday that it had received a research and development tax credit refund of about £0.76m from HMRC.
The AIM-traded point-of-care pharmacogenetic testing company said the refund related to the financial years ended 30 June 2024 and 30 June 2025.

At 1100 BST, shares in Genedrive were up 4% at 1.3p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate

• News Channel